MK 8141

Drug Profile

MK 8141

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals; Merck & Co
  • Class Antihypertensives; Cardiovascular therapies
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
  • 19 Jul 2012 Merck and Actelion terminate their collaboration in renin inhibitors
  • 13 Nov 2008 Discontinued - Phase-II for Hypertension in Puerto Rico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top